Articles found by an AI-assisted PubMed search that may be missing from CancerImmunoDB, shared so that curators and users can see what is being considered.
Why this exists: the database holds only about 10 articles a year for 2021–2024, and a plain PubMed search cannot judge whether a paper fits the scope.
| Year | Screened | Likely relevant |
|---|---|---|
| 2026 | 99 | 61 |
| 2025 | 100 | 81 |
| 2024 | 98 | 72 |
| 2023 | 92 | 45 |
| 2022 | 100 | 52 |
| 2021 | 85 | 49 |
360 articles shown. “In the database” counts the entries the database already has for each drug the AI named (cell line / animal / patient).
| PMID | Year | Article | Drugs | Study type | Cancer type | In the database | Curator status |
|---|---|---|---|---|---|---|---|
| 33529880 | 2021 | Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy. Neoplasia (New York, N.Y.) Likely relevant Tests a novel small molecule PD-L1 inhibitor (APBC) in cell-based assays and a mouse model, and measures cytokine secretions and tumor-infiltrating T cells. | APBC | Mixed | cancer | APBC 0/0/0 | Awaiting curator check |
| 33577301 | 2021 | Metformin Liposome-Mediated PD-L1 Downregulation for Amplifying the Photodynamic Immunotherapy Efficacy. ACS applied materials & interfaces Likely relevant Experimentally tests metformin and IR775 liposome nanoparticles in tumour-bearing animals and measures effects on PD-L1 downregulation and T cells. | metformin; IR775 | Animal | bladder and colon cancers | metformin 0/0/0; IR775 0/0/0 | Awaiting curator check |
| 33617828 | 2021 | Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells. European journal of pharmacology Likely relevant Evaluates the effect of IFN-gamma, a COX-2 inhibitor, and pembrolizumab on cholangiocarcinoma cell lines and their consequent impact on CD8+ T-cell apoptosis. | interferon gamma; rofecoxib; pembrolizumab | Cell line | cholangiocarcinoma | interferon gamma 0/0/0; rofecoxib 0/0/0; pembrolizumab 0/0/16 | Awaiting curator check |
| 33712445 | 2021 | Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. Journal for immunotherapy of cancer Likely relevant Tests HMGB1 inhibitors and immune checkpoint blockade in syngeneic mouse models, measuring changes in various immune cell populations and activation states. | HMGB1 inhibitors; anti-PD-1; anti-PD-L1 | Animal | breast and lung cancer | HMGB1 inhibitors 0/0/0; anti-PD-1 14/36/0; anti-PD-L1 0/15/0 | Awaiting curator check |
| 33722878 | 2021 | IL-1α Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma. Journal of immunology (Baltimore, Md. : 1950) Likely relevant The study experimentally tests rAd.CD40L and anti-PD-L1 in a mouse melanoma model and measures changes in MDSCs, regulatory T cells, cytokines, and PD-L1 expression. | rAd.CD40L; anti-PD-L1 | Animal | melanoma | rAd.CD40L 0/0/0; anti-PD-L1 0/15/0 | Awaiting curator check |
| 33820821 | 2021 | Multiomics analysis reveals a distinct response mechanism in multiple primary lung adenocarcinoma after neoadjuvant immunotherapy. Journal for immunotherapy of cancer Likely relevant Patient study analyzing immune cell infiltration, HLA expression, and T cell function after neoadjuvant pembrolizumab treatment. | pembrolizumab | Patient | lung adenocarcinoma | pembrolizumab 0/0/16 | Awaiting curator check |
| 33826900 | 2021 | Fascin inhibitor increases intratumoral dendritic cell activation and anti-cancer immunity. Cell reports Likely relevant Demonstrates that the fascin inhibitor NP-G2-044 increases intratumoral dendritic cell activation and enhances CD8+ T cell activation when combined with anti-PD-1. | NP-G2-044; anti-PD-1 antibody | Animal | various cancers | NP-G2-044 0/0/0; anti-PD-1 antibody 0/2/0 | Awaiting curator check |
| 33827976 | 2021 | A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma. Science translational medicine Likely relevant The study tests a selective HDAC8 inhibitor and anti-PD-L1 therapy in mouse models and measures T cell infiltration, chemokine production, and memory T cell induction. | HDAC8 inhibitor; anti-PD-L1 | Animal | hepatocellular carcinoma | HDAC8 inhibitor 0/0/0; anti-PD-L1 0/15/0 | Awaiting curator check |
| 33830945 | 2021 | Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation. The Journal of clinical investigation Likely relevant The study tests atractylenolide I in mouse CRC models and human organoids, measuring effects on immunoproteasome activity, MHC-I presentation, and CD8+ T cell cytotoxicity. | atractylenolide I; immune checkpoint blockade | Mixed | colorectal cancer | atractylenolide I 0/0/0; immune checkpoint blockade 0/1/0 | Awaiting curator check |
| 33855973 | 2021 | TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. The Journal of clinical investigation Likely relevant Investigates anti-PD-1/PD-L1 resistance in syngeneic mouse models and measures macrophage polarization and ferroptosis. | anti-PD-1; anti-PD-L1 | Animal | cancer | anti-PD-1 14/36/0; anti-PD-L1 0/15/0 | Awaiting curator check |
| 33909988 | 2021 | Energy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade. Molecular cell Likely relevant Tests anti-CTLA-4 and AMPK agonists in syngeneic mouse models and measures PD-L1 degradation, interferons, and antigen presentation. | anti-CTLA-4; AMPK agonists | Animal | cancer | anti-CTLA-4 1/10/7; AMPK agonists 0/0/0 | Awaiting curator check |
| 33958794 | 2021 | A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. Nature medicine Likely relevant The study treats breast cancer patients with anti-PD1 and chemotherapy and investigates intratumoral immune cell changes using single-cell transcriptome, TCR, and proteome profiling. | anti-PD1; neoadjuvant chemotherapy | Patient | breast cancer | anti-PD1 1/1/0; neoadjuvant chemotherapy 0/0/0 | Awaiting curator check |
| 34103659 | 2021 | PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy. Communications biology Likely relevant Evaluates the small molecule immune checkpoint inhibitor CA-170 in immunocompetent mouse tumor models and measures T cell proliferation and activation. | CA-170 | Animal | tumor models | CA-170 0/0/0 | Awaiting curator check |
| 34119606 | 2021 | Sonodynamic therapy complements PD-L1 immune checkpoint inhibition in a murine model of pancreatic cancer. Cancer letters Likely relevant The study tests sonodynamic therapy combined with anti-PD-L1 in a murine model of pancreatic cancer and measures infiltrating CD4+ and CD8+ T-lymphocytes. | anti-PD-L1 | Animal | pancreatic cancer | anti-PD-L1 0/15/0 | Awaiting curator check |
| 34162872 | 2021 | Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer. Nature communications Likely relevant Examines Notch signaling activation in SCLC cell lines leading to increased APM gene expression and intrinsic tumor immunity. | Cell line | small cell lung cancer | Awaiting curator check | ||
| 34171309 | 2021 | Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. Cell Likely relevant Tests pharmacologic splicing modulation in tumor-bearing animals and evaluates MHC I immunopeptidome and T cell responses. | splicing modulation drugs; checkpoint blockade | Animal | cancer | splicing modulation drugs 0/0/0; checkpoint blockade 0/1/0 | Awaiting curator check |
| 34206051 | 2021 | Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors. International journal of molecular sciences Likely relevant Tests combination therapy of alpha-PD-L1 and gemcitabine in a mouse model and measures cytokine levels, MDSCs, M2 macrophages, and cytotoxic T-cell infiltration. | alpha-PD-L1 antibody; gemcitabine | Animal | gastrointestinal tumors | alpha-PD-L1 antibody 0/0/0; gemcitabine 30/23/10 | Awaiting curator check |
| 34235912 | 2021 | Immune/Hypoxic Tumor Microenvironment Regulation-Enhanced Photodynamic Treatment Realized by pH-Responsive Phase Transition-Targeting Nanobubbles. ACS applied materials & interfaces Likely relevant Demonstrates that a novel nanobubble drug delivery system combining metformin, photodynamic therapy, and PD-L1 blockade reduces immunosuppression and induces antitumor immunity. | chlorin e6; metformin; DPPA-1; anti-PD-L1 peptide | Cell line | triple-negative breast cancer | chlorin e6 0/0/0; metformin 0/0/0; DPPA-1 0/0/0; anti-PD-L1 peptide 0/0/0 | Awaiting curator check |
| 34266948 | 2021 | Targeting Axl favors an antitumorigenic microenvironment that enhances immunotherapy responses by decreasing Hif-1α levels. Proceedings of the National Academy of Sciences of the United States of America Likely relevant Tests genetic and pharmacological targeting of Axl combined with anti-PD-1 in a preclinical model, showing normalization of blood vessels and a proinflammatory tumor microenvironment. | anti-PD-1 | Animal | HER2+ breast cancer | anti-PD-1 14/36/0 | Awaiting curator check |
| 34275267 | 2021 | Injectable Supramolecular Hydrogel for Locoregional Immune Checkpoint Blockade and Enhanced Cancer Chemo-Immunotherapy. ACS applied materials & interfaces Likely relevant The study tests a hydrogel delivering doxorubicin and DPPA-1 peptide in vivo, measuring immunogenic cell death and T-cell-mediated immune responses. | doxorubicin; DPPA-1 peptide | Animal | cancer | doxorubicin 22/9/0; DPPA-1 peptide 0/0/0 | Awaiting curator check |
| 34433253 | 2021 | Combination of Chidamide-Mediated Epigenetic Modulation with Immunotherapy: Boosting Tumor Immunogenicity and Response to PD-1/PD-L1 Blockade. ACS applied materials & interfaces Likely relevant The study experimentally tests chidamide and a PD-L1 inhibitor (BMS-202) on triple-negative breast cancer models, reporting immune readouts such as immunogenic cell death, MHC expression, and T-cell recognition. | chidamide; BMS-202 | Animal | triple-negative breast cancer | chidamide 39/2/1; BMS-202 0/0/0 | Awaiting curator check |
| 34446607 | 2021 | Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy. Science (New York, N.Y.) Likely relevant The study tests anti-PD-L1 combined with bacterial muropeptides in mouse tumor models and measures immune responses. | anti-PD-L1 | Animal | cancer | anti-PD-L1 0/15/0 | Awaiting curator check |
| 34479614 | 2021 | Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy. Journal of experimental & clinical cancer research : CR Likely relevant Investigates MET and PD-L1 blockade in pancreatic cancer cell lines and animal models, measuring PD-L1 levels and lymphocyte infiltration. | MET inhibitors; PD-1/PD-L1 blockade | Mixed | pancreatic cancer | MET inhibitors 0/0/0; PD-1/PD-L1 blockade 0/1/0 | Awaiting curator check |
| 34480981 | 2021 | Effects of exercise and anti-PD-1 on the tumour microenvironment. Immunology letters Likely relevant Experimentally tests anti-PD-1 in tumour-bearing animals and measures its effect on CD8+ T cells in the tumour microenvironment. | anti-PD-1 | Animal | breast cancer and melanoma | anti-PD-1 14/36/0 | Awaiting curator check |
| 34488792 | 2021 | Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells. Journal of nanobiotechnology Likely relevant The study experimentally tests nanodiamond-doxorubicin conjugates and BMS-1 on cancer cells and TAM models, measuring immune readouts such as M1 macrophage repolarization and HMGB1/PD-L1 regulation. | nanodiamond-doxorubicin conjugates; BMS-1 | Mixed | lung cancer | nanodiamond-doxorubicin conjugates 0/0/0; BMS-1 0/0/0 | Awaiting curator check |